CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on | Zendy

Mike Westby | Zendy; Elna van der Ryst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on

Author(s) -

Mike Westby,

Elna van der Ryst

Publication year - 2010

Publication title -

antiviral chemistry and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.919

H-Index - 51

eISSN - 2040-2066

pISSN - 0956-3202

DOI - 10.3851/imp1507

Subject(s) - maraviroc , ccr5 receptor antagonist , clinical trial , human immunodeficiency virus (hiv) , chemokine receptor , medicine , immunology , pharmacology , biology , virology , chemokine , bioinformatics , immune system

The chemokine coreceptor 5 (CCR5) antagonists are antiretroviral agents with an extracellular, host-targeted mechanism of action against HIV. Maraviroc, the first-in-class CCR5 antagonist, received regulatory approval in 2007, becoming the first oral antiretroviral from a new class in more than 10 years. Other compounds in this class are in various stages of clinical development. In 2005, we reviewed the limited clinical data then available on CCR5 antagonists. In this follow-up review, we revisit the field and assess the clinical and virological data that have emerged in the 4 years since, with particular reference to maraviroc for which the most comprehensive data currently exist.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research